濮阳东方医院治阳痿咨询濮阳东方医院男科治疗早泄价格收费合理,濮阳东方看男科价格低,濮阳东方口碑好收费低,濮阳东方医院看妇科病价格透明,濮阳东方医院男科口碑很好价格低,濮阳东方评价好专业,濮阳东方医院治疗早泄可靠吗

HARBIN, Jan. 5 (Xinhua) -- A launching ceremony for the 2012 Sino-Russia Tourism Year was held in northeast China's Heilongjiang province Thursday.The initiative, along with an accompanying initiative to be launched in Russia in 2013, will boost people-to-people exchanges and consolidate Sino-Russian relations, Russian President Dmitry Medvedev said in a statement on Dec. 31, 2011.The initiative is the third of its kind to take place between China and Russia, following Sino-Russia National Year and the Sino-Russia Year of Language held in 2006 and 2009, respectively.The creation of the 2012 Sino-Russia Tourism Year is a vital decision made by leaders of both countries to boost the China-Russia comprehensive strategic partnership of cooperation, said Shao Qiwei, director of China's National Tourism Administration.The tourism year will serve as a platform to display the abundant tourism resources of the two countries, said Grigory Sarishvili, deputy head of the Russia Federal Tourism Agency.Statistics from Russian tourism authorities showed that the number of Chinese tourists to Russia during the first nine months in 2011 saw a year-on-year increase of 52 percent.

NAIROBI, Nov. 15 (Xinhua) -- The UN refugee agency said on Tuesday there has been an outbreak of cholera in Dadaab, the world's largest refugee camp in Kenya, which is believed to have started among new arrivals who had most likely acquired it in Somalia or en route to the camp.The UN High Commissioner for Refugees (UNHCR) said the situation in Dadaab, home to Somalis fleeing famine and conflict, is being exacerbated by heavy rains and accompanying risks of waterborne diseases."Rains and flooding had affected the trucking of water to parts of the camps, and we fear some refugees resorted to using unsafe water from flooded areas," the UN refugee agency said in a statement released in Nairobi.According to UNHCR, there are now 60 cases in the camps, including 10 laboratory-confirmed cases and one refugee death. To manage the outbreak, UNHCR and partners have set up cholera treatment centres for severe cases, it said.The UN agency deplored insecurity which it said continues to affect aid efforts more than a month after the kidnapping of three aid workers in Kenya's Dadaab refugee complex.The UNHCR says insecurity is still hampering aid efforts in the area, despite the deployment of 100 Kenyan policemen in the last month.UNHCR is assisting them with vehicles, shelter and telecommunications equipment."Together with our partners, we are exploring options to gradually resume full operations despite continued security incidents in and around Dadaab. In the meantime, refugees are still receiving life-saving aid, namely food, water and health care," it said.According to the agency, most cases can be managed through oral rehydration solutions (ORS) that can be given at home or at the health posts."We are working with UNICEF and the Ministry of Health to train health workers in the community-based management of diarrhoea so that patients can begin treatment at home," it said.UNHCR said it has increased levels of chlorine, which kills cholera-causing bacteria, at water points in the camps. These, it said, are monitored to make sure they are maintained at the correct levels."We are also promoting hygiene practices among the refugees, especially the use of latrines and hand washing with soap. Each refugee received 250 grams of soap with the latest food distribution and this will continue monthly for several months," UNHCR said.Dadaab is home to more than 400,000 registered refugees, nearly all of them Somali, with an estimated 70,000 people having arrived in July and August as conditions in their homeland rapidly deteriorated.

SAN FRANCISCO, Nov. 11 (Xinhua) -- Google will launch its new music service next week, U.S. media reported on Friday.In an emailed invitation, Google said it will hold an event called "These Go to Eleven" next Wednesday in Los Angeles, which is expected to be the debut of Google Music, tech news website The Verge reported.Google is reported to be adding new features over the current version of its music service, such as a MP3 music store with connection to its social network Google+.According to a separate report from technology news site CNET on Friday, Google has not yet got licensing deals with all four of the major labels -- Universal Music Group, Warner Music Group, Sony Music Entertainment and EMI.Google introduced a beta version of its music service called Music Beta in May, enabling users to upload their entire music libraries for free to Google servers and stream songs from any browser or Android-based devices.Since the search giant failed to come to license agreements with major music labels at the time, Music Beta is essentially a massive cloud storage hard drive.

WASHINGTON, Dec. 28 (Xinhua) -- People with diets high in several vitamins or in omega 3 fatty acids are less likely to have the brain shrinkage associated with Alzheimer's disease than people whose diets are not high in those nutrients, according to a new study published on Wednesday in the online issue of Neurology, the medical journal of the American Academy of Neurology.Those with diets high in omega 3 fatty acids and in vitamins C, D, E and the B vitamins also had higher scores on mental thinking tests than people with diets low in those nutrients. These omega 3 fatty acids and vitamin D are primarily found in fish. The B vitamins and antioxidants C and E are primarily found in fruits and vegetables.In another finding, the study showed that people with diets high in trans fats were more likely to have brain shrinkage and lower scores on the thinking and memory tests than people with diets low in trans fats. Trans fats are primarily found in packaged, fast, fried and frozen food, baked goods and margarine spreads.The study involved 104 people with an average age of 87 and very few risk factors for memory and thinking problems. Blood tests were used to determine the levels of various nutrients present in the blood of each participant. All of the participants also took tests of their memory and thinking skills. A total of 42 of the participants had MRI scans to measure their brain volume. Overall, the participants had good nutritional status, but seven percent were deficient in vitamin B12 and 25 percent were deficient in vitamin D.Study author Gene Bowman, of Oregon Health & Science University in Portland, said that the nutrient biomarkers in the blood accounted for a significant amount of the variation in both brain volume and thinking and memory scores. For the thinking and memory scores, the nutrient biomarkers accounted for 17 percent of the variation in the scores. For brain volume, the nutrient biomarkers accounted for 37 percent of the variation."These results need to be confirmed, but obviously it is very exciting to think that people could potentially stop their brains from shrinking and keep them sharp by adjusting their diet," Bowman said.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Erwinaze to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy to E. coli derived asparaginase and pegapargase chemotherapy drugs used to treat ALL.Acute lymphoblastic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell. White blood cells help the body fight infection and are formed in the bone marrow.Erwinaze is injected directly into the muscle three times a week and works by breaking down one of the body's protein building blocks (the amino acid, asparagine) that is present in the blood, and is necessary for the growth of all cells. Leukemia cells cannot produce this protein building block. When a patient is treated with Erwinaze the leukemia cells die. Normal human cells are able to make enough asparagine for their own needs through biosynthesis and will not be affected by treatment with Erwinaze."The approval of Erwinaze underscores the FDA's commitment to the approval of drugs for conditions with limited patient populations with unmet medical needs using novel trial endpoints," said Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.Side effects associated with Erwinaze treatment include serious allergic reactions, inflammation of the pancreas, high blood levels of liver enzymes, blood clotting, bleeding, nausea, vomiting and high blood sugar.